Why the study?
Do long-acting calcium channel blockers reduce all-cause mortality and cardiovascular events compared with other drugs or placebo?
Population
175,634 patients from 27 randomized controlled trials
Comparison
Long-acting calcium channel blocker (CCB) vs Another drug or placebo/top of therapy
Design
Meta-analysis
Authors
Loading...
Supports broader dihydropyridine CCB use in hypertension to cut death and stroke; confirms mortality benefit versus active comparators.
Do long-acting calcium channel blockers reduce all-cause mortality and cardiovascular events compared with other drugs or placebo?
Long-acting CCBs reduce all-cause mortality compared with active therapy and prevent stroke, but may increase the risk of heart failure compared to active treatment.
Costanzo et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: